Trials / Withdrawn
WithdrawnNCT04420130
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis: a Single-arm, Prospective Study
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Yanqiao Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis. The main purpose of this study is to evaluate the safety and tolerability of Camrelizumab combined with ablation and chemotherapy as a treatment of Pancreatic cancer liver metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Camrelizumab was administered 200mg iv every 3 weeks |
| DRUG | Chemotherapy | The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer. |
| PROCEDURE | Ablation | First give pancreatic cancer patients with liver metastases to ablation of liver metastases |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2022-08-01
- Completion
- 2023-08-01
- First posted
- 2020-06-09
- Last updated
- 2022-10-04
Source: ClinicalTrials.gov record NCT04420130. Inclusion in this directory is not an endorsement.